TREATMENT OF BENIGN LYTIC BONE LESIONS WITH 45S5 BIOACTIVE GLASS: A CASE SERIES.

Objective: To report a series of 9 cases of patients with benign cavitary tumor lesions who underwent intralesional resection (curettage) followed by cavity filling with 45S5 bioactive glass (Aktibone). Methods: This is a therapeutic case series study with level IV evidence. Patients diagnosed with benign lytic bone lesions who had a surgical indication for curettage followed by cavity filling with bioactive glass were included. In the postoperative period, patients underwent imaging examinations, which were qualitatively evaluated by a radiologist who determined the radiological diagnosis and the quality of osseointegration. The presence of imaging abnormalities was also assessed, and statistical analysis was performed. Results: Nine patients were included, 7 males and 2 females. The mean age was 25.8 years. The initial diagnoses varied, with enchondromas being the most frequent. The mean follow-up time after surgery was 8.4 months. All patients underwent preoperative radiographs. Most patients showed good clinical progression and good to partial osseointegration. Conclusion: The results reinforce that 45S5 bioactive glass demonstrates good performance as a bone substitute in benign lytic lesions, providing adequate osseointegration and a low complication rate.